iShares U.S. Pharmaceuticals ETF IHE
107.05 USD -1.36 (-1.25%)
Regular-session close
106.18 -0.87 -0.82%
After hours · Nov 18, 5:44 PM ET
106.95 Day range 108.67
81.36 52-week range 112.29
- YTD
- +26.19%
- 1 year
- +30.77%
News
zacks.com Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)? If you're interested in broad exposure to the Healthcare - Pharma segment of the equity market, look no further than the iShares U.S. Pharmaceuticals ETF (IHE), a passively managed exchange traded…
fool.com Which Is the Better Buy: iShares' Pharma ETF IHE or First Trust's Biotech Fund FBT? iShares U.S. Pharmaceuticals ETF has a lower expense ratio than the First Trust NYSE Arca Biotechnology Index Fund. First Trust NYSE Arca Biotechnology Index Fund maintains a more concentrated…
zacks.com ETFs in Spotlight as FDA Vision Loss Warning Meets Lilly's Sleep Apnea Win Eli Lilly's sleep apnea breakthrough amid the FDA's vision-loss warning puts diversified healthcare ETFs in the spotlight.
zacks.com Pharmaceuticals ETF (IHE) Hits a New 52-Week High For investors seeking momentum, iShares U.S. Pharmaceuticals ETF IHE is probably on the radar. The fund just hit a 52-week high and is up 42.76% from its 52-week low price of $77.52/share.
fool.com Choosing Healthcare ETFs: Why IHE Outperforms IBB for Many Investors The iShares U.S. Pharmaceuticals ETF offers a lower expense ratio and a significantly higher dividend yield than the iShares Biotechnology ETF. The iShares Biotechnology ETF provides exposure to a…
benzinga.com Alphabet Sinks 11.8%, Small Caps Rally on Strong GDP Growth: Stock Market Today Alphabet's capex-heavy quarter drags the Nasdaq 100 lower while GDP beats and the Russell 2000 rallies, with three of four large caps rising.
defenseworld.net Capital Investment Advisors LLC Makes New $630,000 Investment in iShares U.S. Pharmaceuticals ETF $IHE Capital Investment Advisors LLC bought a new position in shares of iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) in the third quarter, according to the company in its most recent filing with the…
fool.com Which Pharmaceutical ETF Is the Better Buy: iShares’ Domestic IHE or VanEck’s Global PPH? IHE has outperformed recently by concentrating in U.S. drugmakers. PPH offers global reach and a higher dividend for investors willing to trade some of that momentum for income.
etftrends.com From Laggard to Leader: The Surprising Comeback of Healthcare Healthcare stocks have finally stepped back into the spotlight. After spending much of the past several years in the shadow of technology and AI, the sector has quietly emerged as one of the year's…
fool.com Which Pharmaceuticals ETF Is the Better Buy: iShares’ IHE or Invesco’s PJP? Pharmaceutical stocks have been one of the best places to invest over the past year. Choosing between these two funds is really a question about how you want to own what comes next.
fool.com Better Pharma ETF: iShares IHE vs. State Street XPH The iShares U.S. Pharmaceuticals ETF is significantly more concentrated than the State Street SPDR S&P Pharmaceuticals ETF, with Eli Lilly accounting for 23.63% of the portfolio. The iShares U.S.…
zacks.com Execution of Pharma Tariffs Brings These ETFs Into Focus Trump's 100% pharma tariff is reshaping the drug industry. Here's how the key pharma ETFs could be affected.
zacks.com Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)? The iShares U.S. Pharmaceuticals ETF (IHE) was launched on May 1, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Pharma segment of the…
seekingalpha.com IHE: Innovation Supports The Outlook, Valuation Limits Conviction iShares U.S. Pharmaceuticals ETF offers concentrated exposure to US pharma, dominated by Johnson and Johnson (22.5%) and Eli Lilly and Company (20.5%). IHE benefits from structural growth in obesity…
seekingalpha.com IHE: Large-Cap Pharma Cools After A Hot Summer I issue a hold rating on the iShares US Pharmaceuticals ETF due to fair valuation and mounting near-term headwinds. IHE's portfolio is highly concentrated, with 43% in JNJ and LLY and top 10 holdings…
fool.com Does iShares Pharma ETF Offer Superior Returns to Invesco's Equal Weight Healthcare Fund? IHE's concentrated pharma holdings delivered 50% returns over one year, while RSPH's equal-weight healthcare approach generated 29%. Risk profiles differ sharply too.
fool.com Is the iShares Pharmaceuticals ETF or iShares Healthcare ETF the Better Fund for 2026? IHE's concentrated pharma focus delivered 50% gains versus IYH's 27.4%, though the broader healthcare fund offers more diversification and $3.9B in assets.
fool.com Pharma ETF or Biotech ETF: Which Matches Your Investing Mindset? IHE delivered 53.2% returns over one year with lower volatility and a 0.37% expense ratio, while PBE's quantitative biotech strategy carries higher risk.
fool.com In Healthcare ETFs, Is iShares Pharma a Better Buy Than VanEck Biotech? VanEck's concentrated 25-stock biotech play offers higher volatility, while iShares' broader pharma exposure delivered a 1.4% dividend yield and lower drawdown risk.
fool.com IHE vs. XBI: Pharma Stability or Biotech Growth -- Which Healthcare ETF Is the Better Buy? The iShares U.S. Pharmaceuticals ETF (IHE) offers a higher dividend yield and significantly lower historical volatility than the State Street SPDR S&P Biotech ETF (XBI). XBI has outperformed IHE on a…
fool.com Fidelity Healthcare ETF vs. iShares Pharma Fund: Which Wins? Fidelity's lower 0.08% fee and broader 338-stock portfolio contrast sharply with iShares' concentrated pharma play, which delivered 60% returns in one year.
